18Dec 2017

EXPRESSION OF CD105 AND CD31 IN BENIGN AND MALIGNANT SALIVARY GLAND TUMORS WITH MYOEPITHELIAL DIFFERENTIATION (A COMPARATIVE STUDY).

  • Assistant lecturer, Oral Pathology Department, Faculty of Dentistry, October 6 University, Egypt.
  • Assistant Professor, Oral and Maxillofacial Pathology Department, Faculty of Dentistry, Cairo University, Egypt.
  • Professor, Oral and Maxillofacial Pathology Department, Faculty of Dentistry, Cairo University, Egypt
  • Professor, Oral Pathology Department, Faculty of Dentistry, Tanta University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background and Aim: One of the strongest prognostic factors in tumor grading is tumor neovasculature. Hence, angiogenesis is an important target to eliminate tumor growth and metastasis. This study was carried out with the aim of evaluating the angiogenesis in salivary gland tumors by assessing microvessel density (MVD) using CD105 and CD31. This work also compared and correlated the expressions of both markers in benign and malignant salivary gland tumors (SGTs) and in grades of malignant tumors with myoepithelial differentiation. Material and Methods: The material of this work consisted of 76 paraffin embedded specimens including 20 benign tumors and 48 malignant tumors with different grades and types and 8 non neoplastic salivary gland tissues. Immunohistochemical staining was performed using both primary mouse monoclonal CD31 and CD105 antibodies for assessment of angiogenesis. Results: All studied cases showed positive CD31 and CD105 immunoreactivity. The study revealed a highly significant increase of CD31-MVD and CD105-MVD in malignant SGTs compared to benign tumors. Also, high grade malignancy demonstrated an increase in MVD when compared to low grade malignancy. In addition, malignant SGTs without myoepithelial cell differentiation showed significantly higher values of CD31-MVD and non significant difference of CD105-MVD compared to those containing myoepithelial cells. CD31-MVD values were always higher than CD105 in all studied cases. Conclusion: CD105 was more accurate in the assessment of tumor angiogenesis compared to the most commonly used CD31 panendothelial marker.

  1. Akagi , Ikeda Y., Sumiyoshi Y., Kimura Y., Kinoshita J., Miyazaki M., et al. (2002): Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery, 131(1 Suppl): S109-13.
  2. Cardoso S., Souza K., Faria P., Eisenberg A., Dias F., Loyola A. (2009): Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior. BMC Cancer; 9: 391.
  3. Chung Y., Hou Y., Pan A. (2004): Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest; 34:107-12.
  4. Costa A., Demasi A., Bonfitto V., Bonfitto J., Furuse C., Ara?jo V., et al. (2008): Angiogenesis in salivary carcinomas with and without myoepithelial differentiation. Virchows Arch; 453: 359-67.
  5. Dallas N., Samuel S., Xia L., Fan F., Gray M., Lim S., et al. (2008): Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res; 14: 1931-37.
  6. DeLisser H.,?Christofidou-Solomidou M.,?Strieter R.,?Burdick M.,?Robinson C.,?Wexler R.,?et al. (1997): Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol; 151: 671-77.
  7. DeYoung B., Wick M., Fitzgibbon J., Sirgi K., Swanson P. (1993): CD31: An immunospecific marker for endothelial differentiation in human neoplasms. Appl Immunol; 1: 97-100.
  8. Dhanuthai K., Sappayatosok K., Yodsanga S., Rojanawatsirivej S., Pausch N., Pitak-Arnnop P. (2013): An analysis of microvessel density in salivary gland tumours: A single centre study. Surgeon; 11 (3): 147- 52.
  9. Duff S., Jeziorska M., Kumar S., Haboubi N., Sherlock D., O'Dwyer S., et al. (2007): Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis; 9:793-800.
  10. Duff S., Li C., Garland J., Kumar S. (2003): CD105 is important for angiogenesis: evidence and potential applications. FASEB J; 17(9): 984-92.
  11. Fonsatti E., Altomonte M., Nicotra M., Natali P., Maio M. (2003): Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene; 22 (42):6557-63.
  12. Fonsatti E., Jekunen A., Kairemo K., Coral S., Snellman M., Nicotra M., et al. (2000): nEndoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res; 6: 2037-43.
  13. Goumans M., Lebrin F., Valdimarsdottir G. (2003): Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med; 13 (7):301-07.
  14. Mitselou A., Galani V., Skoufi U., Arvanitis D., Lampri E., Loachim E. (2016): Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer. Anticancer Res; 36: 2271-80.
  15. Moghadam S.,?Abadi A.,?Mokhtari S. (2015): Immunohistochemical analysis of CD34 expression in salivary gland tumors. J Oral MaxillofacPathol; 19 (1): 30?33.
  16. Nassiri F.,?Cusimano M.,?Scheithauer B.,?Rotondo F.,?Fazio A.,?Yousef G.,?et al. (2011): Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res; 31(6): 2283-90.
  17. Nico B., Benagiano V., Mangieri D., Maruotti , Vacca A., Ribatti D. (2008): Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol; 23: 601-07.
  18. Pusztaszeri M., Seelentag W., Bosman F. (2006): Immunohistochemical Expression of Endothelial Markers CD31, CD34, von Willebrand Factor and Fli-1 in Normal Human Tissues. J Histochem Cytochem.; 54 (4): 385?95.
  19. Rabia A.,?Ebru L.,?Tuba K.,?Didar G.,?Gulhan O.,?Cengiz O. (2015): Warthin's tumor: An unknown pathogenesis: A neoplasm or a reactive hyperplasia? Indian J Pathol Microbiol.; 58 (1): 7-11.
  20. Reinmuth N., Parikh A., Ahmad S., Liu W., Stoeltzing O., Fan F., et al. (2003): Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech; 60:199-207.
  21. Rossi E.,?Sanz-Rodriguez F.,?Eleno N.,?D?well A.,?Blanco F.,?Langa C.,?et al. (2013): Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood; 121 (2):403-15.
  22. Saad R., EL-Gohary Y., Memari E., Liu Y., Silverman J. (2005): Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol; 36, 955-61.
  23. Sebti S., Hamilton A. (2000): Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene; 19: 6566-73.
  24. Sharma S., Sharma M., Sarkar C. (2005): Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology; 46 (5):481-89.
  25. Soares A., Altemani A., de Oliveira T., de Oliveira Fonseca Rodrigues F., Silva?A., Soave , et al. (2015): Comparison of the Blood and Lymphatic Microvessel Density of Pleomorphic Adenoma and Basal Cell Adenoma. Clin Med Insights Pathol; 8: 17?21.
  26. Tadbir A., Pardis S., Ashkavandi Z., Najvani A., Ashraf M., Taheri A., et al. (2012): Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors.?Asian Pac J Cancer Prev; 13: 5155?59.
  27. Teymoortash A., Schrader C., Shimoda H., Kato S., Werner J. (2007): Evidence of lymphangiogenesis in Warthin?s tumor of the parotid gland.?Oral Oncol; 43(6):614?18.
  28. Weidner N. (2000): Angiogenesis as a predictor of clinical outcome in cancer patients. Human Pathol; 31(4):403-05.
  29. Weidner N., Semple J., Welch W., Folkman J. (1991): Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med; 324:1-8.
  30. Wong S., Hamel L., Chevalier S., Philip A. (2000): Endoglin expression on human microvascular endothelial cells association with beta glycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem; 267: 5550-60.

[Nadia Fathy Hassabou, Rehab Fawzi Kasem, Heba Ahmed Farag and Nahed Emad El-Din Abo Azma. (2017); EXPRESSION OF CD105 AND CD31 IN BENIGN AND MALIGNANT SALIVARY GLAND TUMORS WITH MYOEPITHELIAL DIFFERENTIATION (A COMPARATIVE STUDY). Int. J. of Adv. Res. 5 (Dec). 1026-1034] (ISSN 2320-5407). www.journalijar.com

Nadia Fathy Hassabou
Assistant lecturer, Oral Pathology Department, Faculty of Dentistry, October 6 ?University, Egypt.

DOI:

Article DOI: 10.21474/IJAR01/6052      
DOI URL: http://dx.doi.org/10.21474/IJAR01/6052

Download Full Paper

Download PDF No. of Downloads: 27 | No. of Views: 129